Comparison · NCT02738801-sae
GLPG1690 600 mg QD vs Placebo QD: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. GLPG1690 600 mg QD vs Placebo QD: serious adverse events. Trial comparisons, record NCT02738801-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02738801-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0588 | 0.0105 | 0.27 | wilson | |
| Risk in group 2 | 0.333 | 0.0968 | 0.7 | wilson | |
| Risk difference, group 1 minus group 2 | -0.275 | -0.644 | 0.0425 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.176 | 0.0193 | 1.61 | log | |
| Odds ratio, group 1 over group 2 | 0.125 | 0.00893 | 1.75 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on GLPG1690 600 mg QD than on Placebo QD | 3.64 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | GLPG1690 600 mg QD | Participants received 600 mg GLPG1690, administered as oral capsules QD for 12 weeks. | 1 | 17 | EG001 |
| Group 2 | Placebo QD | Participants received matching oral capsules QD for 12 weeks. | 2 | 6 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From Screening to final follow-up visit (Day 98)
Source ClinicalTrials.gov
Trial
- Title
- Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- NCT number
- NCT02738801
- Phases
- PHASE2
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- GLPG1690 600 mg QD, Placebo QD
- Lead sponsor
- Lakefront Biotherapeutics NV
- Results first posted
- 2020-11-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02738801?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02738801-sae